UCB will perform a 12-week clinical study to compare the efficacy of flagship product Cimzia with Abbott Laboratories' best-seller Humira in patients with rheumatoid arthritis. Both are injectable drugs that work by inhibiting tumor necrosis factor. "We believe the study will provide additional evidence that the ability to make an informed and early treatment decision is important for the treatment of this severe and progressing disease," said Iris Loew-Friedrich, UCB's chief medical officer.

Related Summaries